Skip to main content

Advertisement

Table 1 Characteristics of included patients in our cohort

From: EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Characteristicsn (%)
Total54 (100)
Age at start of osimertinib, years
 Median (range)58 (31–83)
  < 6029 (53.7)
  ≥ 6025 (46.3)
Sex
 Female35 (64.8)
 Male19 (35.2)
Smoker
 Never40 (74.1)
 Ever11 (20.4)
 Unknown3 (5.6)
Histology
 Adenocarcinoma52 (96.3)
 Adenosquamous carcinoma2 (3.7)
Brain metastases
 Yes26 (48.1)
 None28 (51.9)
Line of therapy
 1st/2nda38 (70.4)
 3rd or more16 (29.6)
NGS platform
 BGIb29 (53.7)
 OrigiMed25 (46.3)
EGFR activating mutation
 Exon 19 deletion40 (74.1)
 Exon 21 L858R14 (25.9)
TP53 status
 Mutated33 (61.1)
 Wild type21 (38.9)
  1. NGS next-generation sequencing, EGFR epidermal growth factor receptor
  2. aThree patients had de novo T790M mutation and osimertinib were the first-line therapy
  3. bTwo samples analyzed with an upgrading BGI OseqT NGS panel